Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
ACTIVE_NOT_RECRUITING
Status
Conditions
- Fallopian Tube Endometrioid Tumor
- Fallopian Tube High Grade Serous Adenocarcinoma
- Malignant Ovarian Endometrioid Tumor
- Ovarian High Grade Serous Adenocarcinoma
- Platinum-Sensitive Fallopian Tube Carcinoma
- Platinum-Sensitive Ovarian Carcinoma
- Platinum-Sensitive Primary Peritoneal Carcinoma
- Primary Peritoneal High Grade Serous Adenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Fallopian Tube Endometrioid Adenocarcinoma
- Recurrent Ovarian Endometrioid Adenocarcinoma
- Recurrent Ovarian Serous Adenocarcinoma
- Recurrent Primary Peritoneal Carcinoma
- Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
Interventions
- PROCEDURE: Biospecimen Collection
- PROCEDURE: Computed Tomography
- PROCEDURE: Magnetic Resonance Imaging
- DRUG: Olaparib
- BIOLOGICAL: Tremelimumab
Sponsor
National Cancer Institute (NCI)
Collaborators